Comparing the aspartate aminotransferase (AST) to platelet ratio index (APRI) between African American and white veterans with chronic hepatitis C

Southern Medical Journal

Volumn 104, Issue 5, 2011, Pages 309-314

  Burton, Mary Jane ^a,b,c   Sunesara, Imran ^a,b,c   Penman, Alan ^a,b,c   Pham, Huan ^a,b,c   Oliver, Nora ^a,b,c   Young, Casey A ^a,b,c   McGloster, Novell ^a,b,c   McGuire, Brendan M ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

African Americans; healthcare disparities; hepatitis C; liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUCASIAN; CHRONIC HEPATITIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEMATOLOGICAL PARAMETERS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE PROCEDURE; PLATELET RATIO INDEX; PREDICTIVE VALUE; RACE DIFFERENCE; SCORING SYSTEM; UNITED STATES; VETERAN;

AFRICAN AMERICANS; ASPARTATE AMINOTRANSFERASES; BIOPSY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPATITIS C; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; VETERANS;

EID: 79955622337     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e318213cf52     Document Type: Article

References (32)

1. Yu L, Sloane DA, Guo C, et al. Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol. 2006;4:355-360. (Pubitemid 43343893)
2. Di Bisceglie AM, Lyra AC, Schwartz M, et al. Hepatitis CYrelated hepatocellular carcinoma in the United States: Influence of ethnic status. Am J Gastroenterol. 2003;98:2060-2063. (Pubitemid 37185806)
3. Organ procurement and transplantation network. US liver transplants performed: January 1, 1988-October 31, 2009. Available at: At http:// optn.transplant.hrsa.gov. Accessed January 27, 2009.
4. Alter MJ, Kruszon-Moran D, Nainan OV. The prevalence of hepatitis C virus infection in the United States, 1998-1994. N Engl J Med. 1999;341: 556-562. (Pubitemid 29384163)
5. Seeff LB, Miller RN, Rabkin CS, et al. 45 year follow-up on hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132:105-111. (Pubitemid 30044176)
6. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975-2005. J Clin Oncol. 2009;27:1485-1491.
7. Nguyen MH, Whittemore AS, Garcia RT, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol. 2004;2:820-824. (Pubitemid 39200721)
8. Muir AJ, Bornstein JD, Killinberg PG; Atlantic Coast Hepatitis Treatment Group. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350: 2265-2271. (Pubitemid 38669209)
9. Jacobson IM, Brown RS, McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007;46:982-990. (Pubitemid 350144762)
10. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49:1335-1374.
11. Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526. (Pubitemid 36919874)
12. Lieber CS, Weiss DG, Morgan TR, et al. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol. 2006;101:1500-1508. (Pubitemid 43980623)
13. Snyder N, Gajula L, Xiao S-Y, et al. APRI: An easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol. 2006;40: 535-542. (Pubitemid 44318139)
14. Shaheen AAM, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis CYrelated fibrosis: A systematic review. Hepatology. 2007;46: 912-921. (Pubitemid 47436137)
15. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: The Knodell histology activity index and beyond. Hepatology. 2000, 31:241-246. (Pubitemid 30033714)
16. Perkins NJ, Schisterman EF. The inconsistency of ''optimal'' cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006;163:670-675.
17. Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: Its natural history and histological perspective. Am J Gastroenterol. 2002; 97:700-706. (Pubitemid 34245901)
18. Siddiqui FA, Ehrinpreis MN, Janisse J, et al. Demographics of a large cohort of urban chronic hepatitis C patients. Hepatol Int. 2008;2:376-381.
19. El-Serag H, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750. (Pubitemid 29114292)
20. Wilson L, Torbenson M, Astemborski J, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology. 2006, 43:788-795.
21. Cheung RC, Currie S, Shen H, et al. Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol. 2008;42:827-834.
22. Sebastiani G, Vario A, Guido M, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006;44:686-693.
23. Bourliere M, Penaranda G, Renou C, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: Proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat. 2006;13:659-670. (Pubitemid 44401194)
24. Leroy V, Hilleret MN, Sturm N, et al. Prospective comparison of six noninvasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2006;46:775-782.
25. Salles N, Dussarat P, Foucher J, et al. Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients. Gastroentérol Clin Biol. 2009;33:126-132.
26. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999, 29:1215-1219. (Pubitemid 29168757)
27. Hu KQ, Nyulo NL, Esrailian E, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: A retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40: 147-154. (Pubitemid 38064724)
28. Poynard T, Munteaneu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem. 2004;50:1344-1355. (Pubitemid 38970641)
29. Halfon P, Bacq Y, De Muret A, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol. 2007, 46:395-402. (Pubitemid 46201720)
30. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-832.
31. Pohl A, Behling C, Oliver D, et al. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001;96:3142-3146. (Pubitemid 33095354)
32. Regev A, Behro M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-2618.